Do analysts prefer PYRGF or VTVT?

vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 77.59%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Does the media refer more to PYRGF or VTVT?

In the previous week, vTv Therapeutics had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for vTv Therapeutics and 2 mentions for PyroGenesis Canada. vTv Therapeutics' average media sentiment score of 1.48 beat PyroGenesis Canada's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RFL or PYRGF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor RFL or PYRGF?

In the previous week, Rafael and Rafael both had 2 articles in the media. PyroGenesis Canada's average media sentiment score of 0.00 beat Rafael's score of -1.00 indicating that PyroGenesis Canada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rafael 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AARD or PYRGF?

In the previous week, Aardvark Therapeutics had 25 more articles in the media than PyroGenesis Canada. MarketBeat recorded 27 mentions for Aardvark Therapeutics and 2 mentions for PyroGenesis Canada. Aardvark Therapeutics' average media sentiment score of 0.13 beat PyroGenesis Canada's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VANI or PYRGF?

Vivani Medical presently has a consensus target price of $3.75, suggesting a potential upside of 197.62%. Given Vivani Medical's stronger consensus rating and higher probable upside, research analysts clearly believe Vivani Medical is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer VANI or PYRGF?

In the previous week, Vivani Medical had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Vivani Medical and 2 mentions for PyroGenesis Canada. Vivani Medical's average media sentiment score of 0.83 beat PyroGenesis Canada's score of 0.00 indicating that Vivani Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PYPD or PYRGF?

PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 112.63%. Given PolyPid's stronger consensus rating and higher probable upside, research analysts clearly believe PolyPid is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

PyroGenesis Canada (PYRGF) Competitors

$0.14 0.00 (-1.34%)

As of 09/14/2026 11:18 AM Eastern

Compare

PYRGF vs. VTVT, RFL, AARD, VANI, and PYPD

Should you buy PyroGenesis Canada stock or one of its competitors? PyroGenesis Canada's main competitors and comparable companies include vTv Therapeutics (VTVT), Rafael (RFL), Aardvark Therapeutics (AARD), Vivani Medical (VANI), and PolyPid (PYPD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PyroGenesis Canada compare to vTv Therapeutics?

PyroGenesis Canada (NASDAQ:PYRGF) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

PyroGenesis Canada has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

vTv Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
vTv Therapeutics	N/A	-6.27%	-5.06%

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, vTv Therapeutics had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for vTv Therapeutics and 2 mentions for PyroGenesis Canada. vTv Therapeutics' average media sentiment score of 1.48 beat PyroGenesis Canada's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PyroGenesis Canada has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.47	-$21.12M	-$0.04	N/A
vTv Therapeutics	$1.02M	121.44	-$26.97M	-$1.06	N/A

vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 77.59%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

vTv Therapeutics beats PyroGenesis Canada on 11 of the 17 factors compared between the two stocks.

How does PyroGenesis Canada compare to Rafael?

Rafael (NYSE:RFL) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

PyroGenesis Canada has higher revenue and earnings than Rafael. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$980K	116.73	-$30.52M	-$0.68	N/A
PyroGenesis Canada	$9.14M	3.47	-$21.12M	-$0.04	N/A

Rafael has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

11.3% of Rafael shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 32.9% of Rafael shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PyroGenesis Canada has a net margin of -115.14% compared to Rafael's net margin of -3,321.74%. PyroGenesis Canada's return on equity of 0.00% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
PyroGenesis Canada	-115.14%	N/A	-60.81%

In the previous week, Rafael and Rafael both had 2 articles in the media. PyroGenesis Canada's average media sentiment score of 0.00 beat Rafael's score of -1.00 indicating that PyroGenesis Canada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PyroGenesis Canada beats Rafael on 8 of the 13 factors compared between the two stocks.

How does PyroGenesis Canada compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Aardvark Therapeutics has a beta of 3.74, indicating that its share price is 274% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Aardvark Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 176.28%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aardvark Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PyroGenesis Canada has higher revenue and earnings than Aardvark Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
PyroGenesis Canada	$9.14M	3.47	-$21.12M	-$0.04	N/A

0.0% of PyroGenesis Canada shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aardvark Therapeutics had 25 more articles in the media than PyroGenesis Canada. MarketBeat recorded 27 mentions for Aardvark Therapeutics and 2 mentions for PyroGenesis Canada. Aardvark Therapeutics' average media sentiment score of 0.13 beat PyroGenesis Canada's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aardvark Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Summary

Aardvark Therapeutics beats PyroGenesis Canada on 9 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

PyroGenesis Canada has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
PyroGenesis Canada	$9.14M	3.47	-$21.12M	-$0.04	N/A

Vivani Medical has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 53.3% of Vivani Medical shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Vivani Medical had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Vivani Medical and 2 mentions for PyroGenesis Canada. Vivani Medical's average media sentiment score of 0.83 beat PyroGenesis Canada's score of 0.00 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vivani Medical presently has a consensus target price of $3.75, suggesting a potential upside of 197.62%. Given Vivani Medical's stronger consensus rating and higher probable upside, research analysts clearly believe Vivani Medical is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vivani Medical has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Summary

Vivani Medical beats PyroGenesis Canada on 9 of the 15 factors compared between the two stocks.

How does PyroGenesis Canada compare to PolyPid?

PolyPid (NASDAQ:PYPD) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, PyroGenesis Canada had 1 more articles in the media than PolyPid. MarketBeat recorded 2 mentions for PyroGenesis Canada and 1 mentions for PolyPid. PolyPid's average media sentiment score of 0.93 beat PyroGenesis Canada's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Positive
PyroGenesis Canada	Neutral

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PolyPid has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

PolyPid has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
PyroGenesis Canada	-115.14%	N/A	-60.81%

PyroGenesis Canada has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
PyroGenesis Canada	$9.14M	3.47	-$21.12M	-$0.04	N/A

PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 112.63%. Given PolyPid's stronger consensus rating and higher probable upside, research analysts clearly believe PolyPid is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PyroGenesis Canada beats PolyPid on 8 of the 15 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYRGF vs. The Competition

Export

Metric	PyroGenesis Canada	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.69M	$12.48B	$7.16B	$14.29B
Dividend Yield	N/A	2.64%	2.57%	11.70%
P/E Ratio	-2.33	794.72	273.30	25.37
Price / Sales	3.47	756.68	666.61	88.28
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	-14.00	10.44	10.39	6.24
Net Income	-$21.12M	$2.84B	$3.49B	$358.08M
7 Day Performance	-8.02%	-2.38%	-1.12%	-0.70%
1 Month Performance	-5.08%	1.37%	0.59%	-2.76%
1 Year Performance	-25.49%	4.51%	20.20%	6.72%

PyroGenesis Canada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYRGF PyroGenesis Canada	N/A	$0.14 -1.3%	N/A	-27.5%	$31.69M	$9.14M	N/A	90	News Coverage Gap Up
VTVT vTv Therapeutics	3.6037 of 5 stars	$33.35 -0.4%	$55.83 +67.4%	+58.5%	$131.84M	$36.84M	N/A	9	Positive News
RFL Rafael	0.1526 of 5 stars	$2.60 +5.3%	N/A	+63.0%	$128.44M	$920K	N/A	20	News Coverage Short Interest Increase
AARD Aardvark Therapeutics	3.4336 of 5 stars	$5.38 -6.1%	$15.33 +185.0%	-35.4%	$125.40M	N/A	N/A	18	High Trading Volume
VANI Vivani Medical	4.1075 of 5 stars	$1.49 +7.2%	$3.75 +151.7%	+4.1%	$125.38M	N/A	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYRGF) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. VTVT, RFL, AARD, VANI, and PYPD

How does PyroGenesis Canada compare to vTv Therapeutics?

Summary

How does PyroGenesis Canada compare to Rafael?

Summary

How does PyroGenesis Canada compare to Aardvark Therapeutics?

Summary

How does PyroGenesis Canada compare to Vivani Medical?

Summary

How does PyroGenesis Canada compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. VTVT, RFL, AARD, VANI, and PYPD

How does PyroGenesis Canada compare to vTv Therapeutics?

Which has more volatility and risk, PYRGF or VTVT?

Is PYRGF or VTVT more profitable?

Do insiders & institutionals believe in PYRGF or VTVT?

Does the media refer more to PYRGF or VTVT?

Which has stronger valuation & earnings, PYRGF or VTVT?

Do analysts prefer PYRGF or VTVT?

Summary

How does PyroGenesis Canada compare to Rafael?

Which has preferable valuation & earnings, RFL or PYRGF?

Which has more volatility & risk, RFL or PYRGF?

Do analysts prefer RFL or PYRGF?

Do insiders and institutionals hold more shares of RFL or PYRGF?

Is RFL or PYRGF more profitable?

Does the media favor RFL or PYRGF?

Summary

How does PyroGenesis Canada compare to Aardvark Therapeutics?

Which has more risk & volatility, AARD or PYRGF?

Do analysts recommend AARD or PYRGF?

Which has stronger earnings & valuation, AARD or PYRGF?

Do insiders & institutionals hold more shares of AARD or PYRGF?

Does the media prefer AARD or PYRGF?

Is AARD or PYRGF more profitable?

Summary

How does PyroGenesis Canada compare to Vivani Medical?

Which has better valuation & earnings, VANI or PYRGF?

Which has more volatility & risk, VANI or PYRGF?

Do insiders and institutionals hold more shares of VANI or PYRGF?

Does the media prefer VANI or PYRGF?

Do analysts recommend VANI or PYRGF?

Is VANI or PYRGF more profitable?

Summary

How does PyroGenesis Canada compare to PolyPid?

Does the media prefer PYPD or PYRGF?

Do institutionals & insiders hold more shares of PYPD or PYRGF?

Which has more volatility & risk, PYPD or PYRGF?

Is PYPD or PYRGF more profitable?

Which has better earnings & valuation, PYPD or PYRGF?

Do analysts rate PYPD or PYRGF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools